249 related articles for article (PubMed ID: 30673118)
21. HCV disease burden and population segments in Switzerland.
Bihl F; Bruggmann P; Castro Batänjer E; Dufour JF; Lavanchy D; Müllhaupt B; Negro F; Razavi H; Scheidegger C; Semela D; Semmo N; Blach S
Liver Int; 2022 Feb; 42(2):330-339. PubMed ID: 34839578
[TBL] [Abstract][Full Text] [Related]
22. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
[TBL] [Abstract][Full Text] [Related]
23. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
[TBL] [Abstract][Full Text] [Related]
24. Modelling the Impact and Cost-effectiveness of Extended Hepatitis C Virus Screening and Treatment with Direct-acting Antivirals in a Swiss Custodial Setting.
Girardin F; Hearmon N; Castro E; Negro F; Eddowes L; Gétaz L; Wolff H
Clin Infect Dis; 2019 Nov; 69(11):1980-1986. PubMed ID: 30715266
[TBL] [Abstract][Full Text] [Related]
25. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA
Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250
[TBL] [Abstract][Full Text] [Related]
26. Chronic hepatitis C in the Czech Republic: Forecasting the disease burden.
Fraňková S; Urbánek P; Husa P; Němeček V; Razavi H; Razavi-Shearer D; Chlíbek R; Šperl J
Cent Eur J Public Health; 2019 Jun; 27(2):93-98. PubMed ID: 31241282
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis C virus elimination in Swiss opioid agonist therapy programmes - the SAMMSU cohort.
Bregenzer A; Bruggmann P; Castro E; Moriggia A; Rothen M; Thurnheer MC; Vernazza P; Scheidegger C
Swiss Med Wkly; 2021 Mar; 151():w20460. PubMed ID: 33705563
[TBL] [Abstract][Full Text] [Related]
28. Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?
Kondili LA; Blach S; Razavi H; Craxì A
Ann Ist Super Sanita; 2020; 56(3):325-329. PubMed ID: 32959798
[TBL] [Abstract][Full Text] [Related]
29. REtrieval And cure of Chronic Hepatitis C (REACH): Results of micro-elimination in the Utrecht province.
Kracht PAM; Arends JE; van Erpecum KJ; Thijsen SFT; Vlaminckx BJM; Weersink AJL; Wensing AMJ; Deege MPH; Dimmendaal M; Stadhouders PHGM; Friederich PW; Verhagen MAMT; Boland GJ; Hoepelman AIM
Liver Int; 2019 Mar; 39(3):455-462. PubMed ID: 30204289
[TBL] [Abstract][Full Text] [Related]
30. Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland.
Müllhaupt B; Bruggmann P; Bihl F; Blach S; Lavanchy D; Razavi H; Semela D; Negro F
PLoS One; 2015; 10(6):e0125214. PubMed ID: 26107467
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis C screening in Lithuania: first-year results and scenarios for achieving WHO elimination targets.
Petkevičienė J; Voeller A; Čiupkevičienė E; Razavi-Shearer D; Liakina V; Jančorienė L; Kazėnaitė E; Zaksas V; Urbonas G; Kupčinskas L
BMC Public Health; 2024 Apr; 24(1):1055. PubMed ID: 38622549
[TBL] [Abstract][Full Text] [Related]
32. Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift.
Aljumah AA; Abaalkhail F; Al-Ashgar H; Assiri A; Babatin M; Al Faleh F; Alghamdi A; Al-Hakeem R; Hashim A; Alqutub A; Razavi H; Sanai FM; Al-Swat K; Schmelzer J; Altraif I
Saudi J Gastroenterol; 2016; 22(4):269-81. PubMed ID: 27488321
[TBL] [Abstract][Full Text] [Related]
33. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations.
Omran D; Alboraie M; Zayed RA; Wifi MN; Naguib M; Eltabbakh M; Abdellah M; Sherief AF; Maklad S; Eldemellawy HH; Saad OK; Khamiss DM; El Kassas M
World J Gastroenterol; 2018 Oct; 24(38):4330-4340. PubMed ID: 30344418
[TBL] [Abstract][Full Text] [Related]
34. Impact of new direct-acting antiviral therapy on the prevalence and undiagnosed proportion of chronic hepatitis C infection.
Forouzannia F; Hamadeh A; Passos-Castilho AM; Erman A; Yu A; Feng Z; Janjua NZ; Sander B; Greenaway C; Wong WWL
Liver Int; 2024 Jun; 44(6):1383-1395. PubMed ID: 38445848
[TBL] [Abstract][Full Text] [Related]
35. Achieving WHO recommendations for Hepatitis C Virus Elimination in Belgium.
Bourgeois S; Blach S; Blach C; Laleman W; Matheï C; Mulkay JP; Ravazi H; Robaeys G; Stärkel P; Van Damme P; Van Vlierberghe H; Vandijck D; Vandijck C
Acta Gastroenterol Belg; 2016; 79(2):222-6. PubMed ID: 27382942
[TBL] [Abstract][Full Text] [Related]
36. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
Michielsen P; Ho E; Francque S
Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005
[TBL] [Abstract][Full Text] [Related]
37. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States.
Durham DP; Skrip LA; Bruce RD; Vilarinho S; Elbasha EH; Galvani AP; Townsend JP
Clin Infect Dis; 2016 Feb; 62(3):298-304. PubMed ID: 26628566
[TBL] [Abstract][Full Text] [Related]
38. Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland.
Bachofner J; Valli PV; Bergamin I; Kröger A; Künzler P; Baserga A; Braun DL; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens J; The Swiss Hepatitis C Cohort Study
Swiss Med Wkly; 2018; 148():w14560. PubMed ID: 29376557
[TBL] [Abstract][Full Text] [Related]
39. Estimates on HCV disease burden worldwide - filling the gaps.
Wedemeyer H; Dore GJ; Ward JW
J Viral Hepat; 2015 Jan; 22 Suppl 1():1-5. PubMed ID: 25560838
[TBL] [Abstract][Full Text] [Related]
40. Forecasting the disease burden of chronic hepatitis C virus in Poland.
Flisiak R; Halota W; Tomasiewicz K; Kostrzewska K; Razavi HA; Gower EE
Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):70-6. PubMed ID: 25426979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
